Stocks Health care BRTX
NASDAQ · Health careBioRestorative Therapies, Inc. (BRTX)
BioRestorative Therapies, Inc. brought in $357.9K of revenue over the twelve months to March 31, 2026, down 8.5% from a year earlier. It posted a net loss of $11.1M. In fiscal 2025 capital spending exceeded operating cash flow by $10.9M. At March 31, 2026 it held $3.1M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on May 14, 2026.
What BioRestorative Therapies, Inc. does
BioRestorative Therapies, Inc. is registered with the SEC under industry code SIC 8090 (Services-Misc Health & Allied Services, NEC). Its shares trade on NASDAQ under the ticker BRTX.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $359.7K | -$14.2M | -$1.58 | -$10.9M |
| 2024 | $401K | -$9M | -$1.16 | -$8.3M |
| 2023 | $145.8K | -$10.4M | -$2.47 | -$6.6M |
| 2022 | $119.8K | -$13.2M | -$3.65 | -$6.2M |
| 2021 | $46K | -$44.3M | -$37.30 | -$3.4M |
| 2020 | $77K | -$11.3M | -$28.56 | n/a |
Where BRTX ranks in Health care
Latest SEC filings
What BioRestorative Therapies, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- September 11, 2026
- September 10, 2026Auditor change 8-K/A
- September 2, 2026
- September 2, 2026
- August 25, 2026
- August 14, 2026Late quarterly report notice NT 10-Q
- August 14, 2026Other event 8-K
- August 3, 2026Passive stake changed SCHEDULE 13G/A
- July 16, 2026
- June 12, 2026
Who owns BRTX
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Auctus Fund, LLC13G, passive with 3 related filers | 9.9% | May 15, 2026 |
Largest institutional holders
Insiders
Questions about BRTX
What does BioRestorative Therapies, Inc. do?
BioRestorative Therapies, Inc. is registered with the SEC under industry code SIC 8090 (Services-Misc Health & Allied Services, NEC). Its shares trade on NASDAQ under the ticker BRTX.
Is BioRestorative Therapies, Inc. profitable?
No. Over the twelve months to March 31, 2026 it reported a net loss of $11.1M on revenue of $357.9K.
How much revenue does BioRestorative Therapies, Inc. make?
Over the twelve months to March 31, 2026 BioRestorative Therapies, Inc. reported revenue of $357.9K. That is 8.5% less than a year earlier.
When did BioRestorative Therapies, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on May 14, 2026. It covers the period to March 31, 2026. Its newest filing of any kind is the executive or director change from September 11, 2026.
Similar companies
Compare BRTX with
Follow BRTX
Get an email when BioRestorative Therapies, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Follow BRTX: get an email when it filesWhere the numbers come from
Financial figures are the values BioRestorative Therapies, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.